Association of physical activity with lipodystrophy syndrome in HIV-infected patients

Journal of AIDS and Clinical Research

Volumn 3, Issue 8, 2012, Pages

  Trevisol, Fabiana Schuelter ^a,b   Alencastro, Paulo R ^c   Ribeiro, Paula A B ^a   Wollf, Fernando H ^c   Ikeda, Maria Letícia R ^a   Barcellos, Nêmora T ^c   Brandão, Ajácio B M ^c   Fuchs, Sandra C ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Exercise; HIV AIDS; Lifestyle; Lipodystrophy; Physical activity

Indexed keywords

EID: 84879801111     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000177     Document Type: Article

References (51)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
2. Baril JG, Junod P, Leblanc R, Dion H, Therrien R, et al. (2005) HIV-associated lipodystrophy syndrome: A review of clinical aspects. Can J Infect Dis Med Microbiol 16: 233-243.
3. Kravcik S (2000) HIV lipodystrophy: a review. HIV Clin Trials 1: 37-50.
4. Bodasing N, Fox R (2003) HIV-associated lipodystrophy syndrome: assessment and management. J Infect 46: 87-93.
5. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, et al. (1994) Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 24: 416-420.
6. Carr A (2003) HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17: S141-148.
7. Bergersen BM, Sandvik L, Bruun JN, Tonstad S (2004) Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 23: 625-630.
8. Collins RL, Kanouse DE, Gifford AL, Senterfitt JW, Schuster MA, et al. (2001) Changes in health-promoting behavior following diagnosis with HIV: prevalence and correlates in a national probability sample. Health Psychol 20: 351-360.
9. Thoni GJ, Fedou C, Brun JF, Fabre J, Renard E, et al. (2002) Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab 28: 397-404.
10. Terry L (2008) HIV and exercise. Journal of the Society of Cardiology of Rio Grande do Sul 15:1-7.
11. Terry L, Sprinz E, Stein R, Medeiros NB, Oliveira J, et al. (2006) Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc 38: 411-417.
12. Roubenoff R, Weiss L, McDermott A, Heflin T, Cloutier GJ, et al. (1999) A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 13: 1373-1375.
13. Azevedo MR, Araújo CL, Reichert FF, Siqueira FV, da Silva MC, et al. (2007) Gender differences in leisure-time physical activity. Int J Public Health 52: 8-15.
14. Jaime PC, Florindo AA, Latorre Mdo R, Segurado AA (2006) Central obesity and dietary intake in HIV/AIDS patients. Rev Saude Publica 40: 634-640.
15. Cui Q, Carruthers S, McIvor A, Smaill F, Thabane L, et al. (2010) Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. AIDS Res Ther 7: 6.
16. Peterson S, Martins CR, Cofrancesco J Jr (2008) Lipodystrophy in the patient with HIV: social, psychological, and treatment considerations. Aesthet Surg J 28: 443-451.
17. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, et al. (2003) Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 32: 48-56.
18. Bogner JR, Vielhauer V, Beckmann RA, Michl G, Wille L, et al. (2001) Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 27: 237-244.
19. Andany N, Raboud JM, Walmsley S, Diong C, Rourke SB, et al. (2011) Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials 12: 89-103.
20. Galli M, Veglia F, Angarano G, Santambrogio S, Meneghini E, et al. (2003) Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 34: 58-61.
21. Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, et al. (2005) Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 40: 1837-1845.
22. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356: 1423-1430.
23. Carr A (2000) HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 30: S135-142.
24. Miller J, Carr A, Emery S, Law M, Mallal S, et al. (2003) HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 4: 293-301.
25. Chen D, Misra A, Garg A (2002) Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 87: 4845-4856.
26. Komiya H, Mori Y, Yokose T, Tajima N (2006) Smoking as a risk factor for visceral fat accumulation in Japanese men. Tohoku J Exp Med 208: 123-132.
27. Domingo P, Sambeat MA, Perez A, Ordonez J, Rodriguez J, et al. (2003) Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. Antivir ther 8: 223-231.
28. Segatto AF, Freitas Junior IF, Santos VR, Alves KC, Barbosa DA, et al. (2011) Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy. Rev Soc Bras Med Trop 44: 420-424.
29. Ramirez-Marrero FA, Smith BA, Melendez-Brau N, Santana-Bagur JL (2004) Physical and leisure activity, body composition, and life satisfaction in HIV-positive Hispanics in Puerto Rico. J Assoc Nurses AIDS Care 15: 68-77.
30. Florindo AA, de Oliveira Latorre Mdo R, Jaime PC, Segurado AA (2007) Leisure time physical activity prevents accumulation of central fat in HIV/AIDS subjects on highly active antiretroviral therapy. Int J STD AIDS 18: 692-696.
31. Smith BA, Neidig JL, Nickel JT, Mitchell GL, Para MF, et al. (2001) Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS 15: 693-701.
32. Carr A, Samaras K, Burton S, Law M, Freund J, et al. (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-58.
33. Guimaraes MM, Greco DB, de O Junior AR, Penido MG, Machado LJ (2007) Corporal fat distribution and lipidic and glicemic profiles of HIV-infected patients. Arq Bras Endocrinol Metabol 51: 42-51.
34. Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, et al. (2008) Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 47: 304-311.
35. Seoane E, Resino S, Micheloud D, Moreno A, de Quiros JC, et al. (2008) Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption. J Acquir Immune Defic Syndr 48: 455-459.
36. Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM (2008) Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. J Acquir Immune Defic Syndr 49: 377-383.
37. Grunfeld C, Feingold KR (1992) Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 327: 329-337.
38. Tsiodras S, Mantzoros C, Hammer S, Samore M (2000) Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 160: 2050-2056.
39. Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JS, et al. (2002) Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol 31: 1016-1020.
40. Tirosh A, Rudich A, Shochat T, Tekes-Manova D, Israeli E, et al. (2007) Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 147: 377-385.
41. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, et al. (2007) Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115: 450-458.
42. Baum MK, Rafie C, Lai S, Xue L, Sales S, et al. (2006) Coronary Heart Disease (CHD) Risk Factors and Metabolic Syndrome in HIV-Positive Drug Users in Miami. Am J Infect Dis 2: 173-179.
43. Boccara F (2008) Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 22: S19-26.
44. Fichtenbaum CJ (2010) Does antiretroviral therapy increase or decrease the risk of cardiovascular disease? Curr HIV/AIDS Rep 7: 92-98.
45. Guedes DP, Goncalves LA (2007) Impact of the habitual physical activity on lipid profile in adults. Arq Bras Endocrinol Metabol 51: 72-78.
46. Healy GN, Dunstan DW, Salmon J, Cerin E, Shaw JE, et al. (2008) Breaks in sedentary time: beneficial associations with metabolic risk. Diabetes Care 31: 661-666.
47. Yamada Y, Matsuo H, Warita S, Watanabe S, Kato K, et al. (2007) Prediction of genetic risk for dyslipidemia. Genomics 90: 551-558.
48. Arendt BM, Aghdassi E, Mohammed SS, Fung LY, Jalali P, et al. (2008) Dietary intake and physical activity in a Canadian population sample of male patients with HIV infection and metabolic abnormalities. Curr HIV Res 6: 82-90.
49. Sheehan LA, Macallan DC (2000) Determinants of energy intake and energy expenditure in HIV and AIDS. Nutrition 16: 101-106.
50. (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421.
51. (2005) I Brazilian guidelines on diagnosis and treatment of metabolic syndrome. Arq Bras Cardiol 84: 1-28.